412 related articles for article (PubMed ID: 34709601)
21. Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia: A Systematic Literature Review and Network Meta-Analysis.
Wojciechowski P; Wilson K; Nazir J; Pustułka I; Tytuła A; Smela B; Pochopien M; Vredenburg M; McCrae KR; Jurczak W
Adv Ther; 2021 Jun; 38(6):3113-3128. PubMed ID: 33934279
[TBL] [Abstract][Full Text] [Related]
22. Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies.
Kuter DJ; Allen LF
Br J Haematol; 2018 Nov; 183(3):466-478. PubMed ID: 30203841
[TBL] [Abstract][Full Text] [Related]
23. Real-world use of avatrombopag in patients with chronic liver disease and thrombocytopenia undergoing a procedure.
Satapathy SK; Sundaram V; Shiffman ML; Jamieson BD
Medicine (Baltimore); 2023 Oct; 102(40):e35208. PubMed ID: 37800793
[TBL] [Abstract][Full Text] [Related]
24. Avatrombopag maleate for the treatment of periprocedural thrombocytopenia in patients with chronic liver disease.
Al-Samkari H
Drugs Today (Barc); 2018 Nov; 54(11):647-655. PubMed ID: 30539164
[TBL] [Abstract][Full Text] [Related]
25. Romiplostim in chronic immune thrombocytopenic purpura.
Cersosimo RJ
Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
[TBL] [Abstract][Full Text] [Related]
26. Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease.
Khemichian S; Terrault NA
Semin Thromb Hemost; 2020 Sep; 46(6):682-692. PubMed ID: 32820479
[TBL] [Abstract][Full Text] [Related]
27. Avatrombopag for the Treatment of Adult Patients with Chronic Immune Thrombocytopenia (cITP): Focus on Patient Selection and Perspectives.
Tsykunova G; Ghanima W
Ther Clin Risk Manag; 2022; 18():273-286. PubMed ID: 35386180
[TBL] [Abstract][Full Text] [Related]
28. Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies.
Poordad F; Terrault NA; Alkhouri N; Tian W; Allen LF; Rabinovitz M
Int J Hepatol; 2020; 2020():5421632. PubMed ID: 32047671
[TBL] [Abstract][Full Text] [Related]
29. Thrombocytopenia in Chronic Liver Disease: New Management Strategies.
Nilles KM; Flamm SL
Clin Liver Dis; 2020 Aug; 24(3):437-451. PubMed ID: 32620282
[TBL] [Abstract][Full Text] [Related]
30. Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2).
Peck-Radosavljevic M; Simon K; Iacobellis A; Hassanein T; Kayali Z; Tran A; Makara M; Ben Ari Z; Braun M; Mitrut P; Yang SS; Akdogan M; Pirisi M; Duggal A; Ochiai T; Motomiya T; Kano T; Nagata T; Afdhal N
Hepatology; 2019 Oct; 70(4):1336-1348. PubMed ID: 30762895
[TBL] [Abstract][Full Text] [Related]
31. Population Pharmacokinetic/Pharmacodynamic Analyses of Avatrombopag in Patients With Chronic Liver Disease and Optimal Dose Adjustment Guide With Concomitantly Administered CYP3A and CYP2C9 Inhibitors.
Nomoto M; Ferry J; Hussein Z
J Clin Pharmacol; 2018 Dec; 58(12):1629-1638. PubMed ID: 29905956
[TBL] [Abstract][Full Text] [Related]
32. Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.
Garnock-Jones KP
Drugs; 2011 Jul; 71(10):1333-53. PubMed ID: 21770480
[TBL] [Abstract][Full Text] [Related]
33. Avatrombopag for the management of thrombocytopenia in patients with chronic liver disease.
Lozano ML
Rev Esp Enferm Dig; 2021 Feb; 113(2):136-140. PubMed ID: 33233913
[TBL] [Abstract][Full Text] [Related]
34. Phase 2 study of avatrombopag in Japanese patients with chronic liver disease and thrombocytopenia.
Eguchi Y; Takahashi H; Mappa S; Santagostino E
Hepatol Res; 2022 Apr; 52(4):371-380. PubMed ID: 35134259
[TBL] [Abstract][Full Text] [Related]
35. Safety, tolerance, pharmacokinetic and pharmacodynamic properties of thrombopoietin mimetic peptide for injection in Chinese healthy volunteers: a randomized, placebo-controlled, double-blind study.
Sheng XY; Liu ZY; Zhao J; Song L; Zhao WM; Zhao X; Cui YM
Platelets; 2022 Nov; 33(8):1185-1191. PubMed ID: 35549802
[TBL] [Abstract][Full Text] [Related]
36. Romiplostim: a review of its use in immune thrombocytopenia.
Keating GM
Drugs; 2012 Feb; 72(3):415-35. PubMed ID: 22316355
[TBL] [Abstract][Full Text] [Related]
37. Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
Orme ME; Bentley R; Marcella S; Peck-Radosavljevic M; Perard R; Wedemeyer H; Yoshiji H; Agarwal K; Dusheiko G
Adv Ther; 2022 Sep; 39(9):4169-4188. PubMed ID: 35836089
[TBL] [Abstract][Full Text] [Related]
38. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.
Al-Samkari H; Kuter DJ
Br J Haematol; 2018 Oct; 183(2):168. PubMed ID: 29978577
[No Abstract] [Full Text] [Related]
39. Avatrombopag increased platelet count in a patient with chronic immune thrombocytopenia refractory to multiple lines of treatment.
Lebowa W; Zdziarska J; Sacha T
Blood Coagul Fibrinolysis; 2023 Jul; 34(5):327-332. PubMed ID: 37395226
[TBL] [Abstract][Full Text] [Related]
40. Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors.
Gao Y; Liu Q; Shen Y; Li Y; Shao K; Ye B; Shen Y; Zhou Y; Wu D
Platelets; 2022 Oct; 33(7):1024-1030. PubMed ID: 35040375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]